Modimelanotide (original) (raw)
Modimelanotide (INN) (code names AP-214, ABT-719, ZP-1480) is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development by, at different times, , Abbott Laboratories, AbbVie, and for the treatment of acute kidney injury. It acts as a non-selective melanocortin receptor agonist, with IC50 values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC1, MC3, MC4, and MC5 receptors. Modimelanotide failed clinical trials for acute kidney injury despite showing efficacy in animal models, and development was not further pursued.
| Property | Value |
|---|---|
| dbo:abstract | Modimelanotide (INN) (code names AP-214, ABT-719, ZP-1480) is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development by, at different times, , Abbott Laboratories, AbbVie, and for the treatment of acute kidney injury. It acts as a non-selective melanocortin receptor agonist, with IC50 values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC1, MC3, MC4, and MC5 receptors. Modimelanotide failed clinical trials for acute kidney injury despite showing efficacy in animal models, and development was not further pursued. (en) |
| dbo:casNumber | 926277-68-1 |
| dbo:fdaUniiCode | 96C1EBE9CG |
| dbo:pubchem | 72941953 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Modimelanotide.svg?width=300 |
| dbo:wikiPageExternalLink | http://www.zealandpharma.com/research-and-development/publications/zp1480_ap214 http://adisinsight.springer.com/drugs/800023137 |
| dbo:wikiPageID | 46801868 (xsd:integer) |
| dbo:wikiPageLength | 6275 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 993704801 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:BMS-470,539 dbr:Melanocortin dbr:Melanocortin_1_receptor dbr:Melanocortin_4_receptor dbr:Melanocortin_5_receptor dbr:Melanocortin_receptor dbr:Bremelanotide dbr:Peptide dbc:Abandoned_drugs dbr:Melanotan_II dbr:Animal_model dbr:Clinical_trial dbr:Acute_kidney_injury dbr:Drug dbr:Melanocortin_3_receptor dbr:AbbVie dbr:Abbott_Laboratories dbr:Afamelanotide dbr:Agonist dbr:PF-00446687 dbr:International_Nonproprietary_Name dbc:Peptides dbc:Melanocortin_receptor_agonists dbr:Setmelanotide dbr:IC50 dbr:Α-melanocyte-stimulating_hormone dbr:Action_Pharma dbr:Zealand_(pharmaceutical_company) |
| dbp:atcPrefix | None (en) |
| dbp:c | 113 (xsd:integer) |
| dbp:casNumber | 926277 (xsd:integer) |
| dbp:chemspiderid | 34988374 (xsd:integer) |
| dbp:h | 181 (xsd:integer) |
| dbp:iupacName | (N2-acetyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-alpha-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valinamide) (en) |
| dbp:n | 33 (xsd:integer) |
| dbp:o | 25 (xsd:integer) |
| dbp:pubchem | 72941953 (xsd:integer) |
| dbp:s | 1 (xsd:integer) |
| dbp:smiles | [H]/N=C/NCCC[C@@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NCC (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | WHRVKPBBRZHWTN-ZHHKRVSMSA-N (en) |
| dbp:synonyms | Acetylhexa-(L)-lysyl-α-MSH (en) |
| dbp:unii | 96 (xsd:integer) |
| dbp:width | 250 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Genito-urinary-drug-stub dbt:Reflist dbt:Fdacite dbt:Melanocortin_receptor_modulators |
| dct:subject | dbc:Abandoned_drugs dbc:Peptides dbc:Melanocortin_receptor_agonists |
| gold:hypernym | dbr:Drug |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Modimelanotide (INN) (code names AP-214, ABT-719, ZP-1480) is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development by, at different times, , Abbott Laboratories, AbbVie, and for the treatment of acute kidney injury. It acts as a non-selective melanocortin receptor agonist, with IC50 values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC1, MC3, MC4, and MC5 receptors. Modimelanotide failed clinical trials for acute kidney injury despite showing efficacy in animal models, and development was not further pursued. (en) |
| rdfs:label | Modimelanotide (en) |
| owl:sameAs | freebase:Modimelanotide yago-res:Modimelanotide wikidata:Modimelanotide https://global.dbpedia.org/id/xq2Q |
| prov:wasDerivedFrom | wikipedia-en:Modimelanotide?oldid=993704801&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Modimelanotide.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Modimelanotide |
| is dbo:wikiPageRedirects of | dbr:ABT-719 dbr:ABT719 dbr:AP-214 dbr:AP214 dbr:ZP-1480 dbr:ZP1480 |
| is dbo:wikiPageWikiLink of | dbr:Melanocortin_1_receptor dbr:Melanocortin_4_receptor dbr:Melanocortin_receptor dbr:Bremelanotide dbr:Melanocyte-stimulating_hormone dbr:BMS-470539 dbr:ABT-719 dbr:ABT719 dbr:AP-214 dbr:AP214 dbr:ZP-1480 dbr:ZP1480 |
| is foaf:primaryTopic of | wikipedia-en:Modimelanotide |
